AUTHOR INDEX

Abrass, C. K., 87
Al-Awqati, Q., 415
Austin, H. A., 2
Avner, E. D., 311

Bagby, S. P., 211
Balow, J. E., 2
Barhanin, J., 438
Baylis, C., 133
Bickel, J. W., 95
Binder, H. J., 405
Blantz, R. C., 242, 272
Brater, D. C., 575
Briggs, J. P., 105
Bushinsky, D. A., 551

Cain, B. D., 431
Campbell, W. G., 431
Caplan, M. J., 421
Cattell, V., 277
Caviston, T. L., 431
Clark, W. F., 77
Codina, J., 399
Cohen, J. J., 95
Courtois-Coutry, N., 421

Dell, K. M., 364
Doucet, A., 390
DuBose, T. D., Jr., 399
Dunbar, L. A., 421

Ellison, D. H., 581

Fogo, A., 148
Forman, A., 487
Foster, M. H., 12, 173
Frassetto, L., 487
Friedman, P. A., 551

Gabbai, F. B., 214, 242
Gabow, P. A., 109
Gelband, C. H., 472
Germino, G. G., 327
Giebisch, G., 421, 458
Gipson, D., 140
Gold, D. P., 288
Goligorsky, M. S., 263
Grishin, A. V., 421
Gross, S. S., 215
Guay-Woodford, L. M., 123, 312, 364

He, J., 494
Hebert, S. C., 504
Hikita, C., 415
Hohenfellner, K., 148

Ingelfinger, J. R., 201

Jevnikar, A. M., 77

Kaplan, N. M., 569
Kashtan, C. E., 353
Katz, L. A., 140
Kelley, V. R., 57, 173
Kelly, C. J., 182, 288
Kieber-Emmons, T., 524
Kincaid-Smith, P., 166
Klahr, S., 304
Kleyman, T. R., 524
Knoers, N. V. A. M., 344
Koh, J. S., 34
Kon, V., 148
Kone, B. C., 230
Korf, B. R., 319
Kosari, F., 524
Kurtzman, N. A., 598

Lakkis, F. G., 25
Lane, P., 215
Laroche-Joubert, N., 390
Laski, M. E., 533
Lesage, F., 438
Levine, J. S., 34
Levison, S. P., 98
Lindberg, J. S., 115

Ma, G., 477
Madaio, M. P., 48
Maldonado, M. M., 503
Meneton, P., 438
Moe, S. M., 115
Monnens, L. L. A. H., 344
Morris, R. C., Jr., 487

Noiri, E., 263

Pajor, A. M., 195
Preisig, P., 87
Pressley, T. A., 533
Purkerson, M. L., 89

Raij, L., 296
Rajendran, V. M., 405
Reinhard, J., 421
Ring, G. H., 25

Sabatini, S., 188
Sangan, P., 405
Satlin, L. M., 155
Scheinman, S. J., 381
Schmidlin, O., 487
Schwalbe, R. A., 389
Schwartz, D., 272
Sebastian, A., 487
Sheng, S., 524
Stehman-Breen, C., 140

Takito, J., 415
Tanaka, M., 487
Thomson, S. C., 251
Tumlin, J. A., 67
Tunstall-Pedoe, H., 500

Vekerdy, L., 89
Vijayakumar, S., 415

Wall, S. M., 399
Wang, T., 421
Warnock, D. G., 374
Watnick, T., 327
Welch, W. J., 251
Wesson, D. E., 1, 86
Whelton, P. K., 494
Wiederholt, T., 415
Wilcox, C. S., 251, 557
Wilson, P. D., 123
Wingo, C. S., 389, 431, 472
Woods, L. L., 201
Wüthrich, R. P., 57

Xia, S.-L., 472

Yan, LB., 415
Young, D. B., 477

SUBJECT INDEX

Absorption
  active K, and colonic H,K-ATPase, 406-408
  Na, transepithelial voltage of CCD principal cells, developmental regulation of K^+ transport and, 158-159
Accelerated vascular disease, as risk factor for morbidity and mortality with renal transplantation for lupus nephritis, 79-81
Access to care for women, equity in, 107
ACE, *see* Angiotensin-converting enzyme; Angiotensin-converting enzyme inhibitors
Acidosis
  diuretic-induced metabolic, 562
  see also Distal renal tubular acidosis
Acquired hypertension and cardiorenal disease, perinatal milieu and, 205-208
Active K (potassium) absorption, and colonic H^+,K^+-ATPase, 406-408
Activity of NOS isoforms in kidney, 232-235
Acute glomerulonephritis (GN), NO role in, 283
Acute renal injury, NO in, 263-271
  cytotoxicity of NO in, 264
  and injury effects on stress-inducible factors, 263
  and neutrophil-endothelial cell adhesion, 264-265
  NO action related to enzymatic source, 269-270
  NO in epithelial wound healing, 265
  NO targets, 264
  NOS expression and, 264
  NOS2 and NOS3 in, *see* NOS2 in acute renal injury; NOS3 in acute renal injury
  therapeutic approaches to limit renal injury and improve renal hemodynamics, 267-268
Adaptation to diuretics, 581-588
  chronic, 585-588
  immediate, 581-583

short-term, 583-585
Adaptation to K^+ depletion, *see* Collecting ducts, adaptation of, to K^+ depletion
Adenosine triphosphatase, *see* H^+-ATPase; K^+-ATPase
Administrative leadership positions, women in, 109-114
Adolescent girls with ESRD, medical issues affecting dialyzed, 144-145
ADPKD, *see* Autosomal dominant polycystic kidney disease
Advanced mesangial IgA (immunoglobulin A) glomerulonephritis (GN), treatment to prevent progression of, 170-171
Adverse drug reactions to diuretics, 565
Adverse effects of diuretics, *see* Metabolic and adverse effects of diuretics
Advocacy for research in women's health issues, as WIN goal, 211
Alcohol metabolism, as NO target, 223
Aldosteronism, *see* Autosomal dominant pseudohypoaldosteronism; Autosomal recessive pseudohypoaldosteronism; Glucocorticoid-responsive aldosteronism
Alkalosis, diuretic-induced metabolic, 562
Allergic encephalomyelitis, NOS2 inhibition effects on, 290-292
Allergic reactions to diuretics, 564-565
Alpha (α) subunit
  of colonic H^+,K^+-ATPase, molecular studies of, 409
  see also Alpha-/subunit of renal H^+,K^+-ATPase
Alpha (α)-subunit of renal H^+,K^+-ATPase, 399-400
  cDNA clones for, 432-434
  $HK\alpha_2$ regulation in renal medulla by chronic hypokalemia, 400-402
Alport syndrome (AS), 314, 353-354
  genetic testing for, 324-325
AME syndrome, *see* Apparent mineralocorticoid excess syndrome
Amiloride, 516, 517
  see also Epithelial Na channel, molecular mechanisms of amiloride effects on
Amino acids, Na,K-dependent glutamate/neutral amino acid family of K transporters, 451-452
Analgesic nephropathy, need for research on, 106-107
Ancillary K (potassium) channel subunits, proteins associated with, 442-444
Anergy, peripheral lymphocyte tolerance to self-antigens and, 26-29
  breakdown of, and induction of autoimmunity, 28-29
  mechanisms of, 26-27
Aneurysms, intracranial, with ADPKD, causes and management of, 125
Angiotensin, *see* Angiotensin-converting enzyme; Angiotensin-converting enzyme inhibitors; Angiotensin II-NO interaction; Renin-angiotensin-aldosterone system; AT_1; AT_1 gene; Renin-angiotensin system; Renin-angiotensin-aldosterone system
Angiotensin-converting enzyme (ACE), role of, in hypertension, 203
Angiotensin-converting enzyme (ACE) inhibitors, IgA glomerulonephritis progression prevented with, 169-171
Angiotensin II-NO interaction, 244-247
  angiotensin II-NO-renal nerve interaction and, 246-247
  hemodynamic effects of, 244-246
  and renin secretion, 246
  tubuloglomerular feedback and, 258-259
Angiotensinogen gene, role of, in hypertension, 203
Animal models, see Experimental models
Anion exchanger, plasticity of H^+-ATPase polarity and kAE1, hensin pathway in intercalated cells and, 415-416
Antenatal (prenatal) diagnosis, ethical issues in, 322-323
Antenatal (prenatal) hypercalciuric Bartter's (hyperprostaglandin E) syndrome, 367-369
Antibodies, *see* Anti-DNA antibodies; Antigen(s) in lupus nephritis, autoantibodies and; Antiphospholipid autoantibodies; Nephritogenic autoantibodies in pathogenesis of lupus nephritis
Antidiuretic action of AVP in distal nephron in NDI, cellular physiology of, 345-346
Anti-DNA (deoxyribonucleic acid) antibodies
  in lupus nephritis, nuclear localization of, through interaction with ubiquitous cell surface antigen, 52-53
  see also Anti-DNA autoantibodies in lupus nephritis
Anti-DNA (deoxyribonucleic acid) autoantibodies in lupus nephritis
  against DNA-histone complexes due to internucleosomal cleavage during apoptosis, 38-39
  immunosuppression and, 69-72
  nephritogenicity of, 41-42, 49-50
Antigen(s), *see* Antigen(s) in lupus nephritis; Antigen specificity; Antigenic determinants; Lymphocyte tolerance to self-antigens, pathogenesis of autoimmunity and
Antigen(s) in lupus nephritis, 50-53
  ubiquitous cell surface, nuclear localization of anti-DNA antibodies through interaction with, 52-53
  see also Antigen(s) in lupus nephritis, autoantibodies and; Autoantigens in lupus nephritis; Lymphocyte tolerance to self-antigens in lupus nephritis
Antigen(s) in lupus nephritis, autoantibodies and, 50-52
  altered antigen binding influencing pathogenicity of autoantibodies, 51-52
  apoptotic antigens as targets for autoantibodies, 37-41
  direct binding of autoantibodies to glomerular antigens, 50-51
Antigen specificity
  of infiltrating T cells in interstitial nephritis, 184
  influence of, on location of immune deposits and inflammatory phenotype in lupus nephritis, 50-51
Antigenic determinants, uncovering of cryptic, and autoimmunity, 29-30
Antiphospholipid (aPL) antibodies in lupus nephritis, renal transplantation and, 79
Antiphospholipid (aPL) autoantibodies, immunization with apoptotic cells and, 41
Antiproliferative agent for T cells, endogenous NO as, 292-294
Apical K^+ (potassium) secretory channels, TAL, 509-512
Apical membranes of tubular cells
  citrate transport across, 195-196
  K recycling across, K channels and, 460-461
aPL, *see* Antiphospholipid antibodies; Antiphospholipid autoantibodies
Apoptosis (programmed cell death)
  failure of passive, and autoimmunity induction, 28
  as NO target, 221-222
  see also Apoptosis, and autoimmunity in lupus nephritis

Apoptosis (programmed cell death), and autoimmunity in lupus nephritis, 34-47
anti-DNA autoantibodies and, *see* Anti-DNA autoantibodies in lupus nephritis
apoptotic antigens as targets for autoantibodies and, 37-41
lymphocyte tolerance and, *see* Lymphocyte tolerance to self-antigens in lupus nephritis
and mechanisms of apoptosis, 34-35
Apparent mineralocorticoid excess (AME) syndrome, 314
described, 377
Mendelian form of hypertension in, 205
AQP, *see* Aquaporin mediated water flux
AQP0 (aquaporin 0), 536
AQP1 (aquaporin 1)/CHIP 28, 536-538
AQP2 (aquaporin 2), 538-540
see also AQP2 gene; AQP2 in pathophysiological states
AQP2 (aquaporin 2) in pathophysiological states, 542-544
in CHF, cirrhosis, 543
in diabetes insipidus, 542-543; *see also* Nephrogenic diabetes insipidus
in nephrotic syndrome, 543-544
AQP2 gene in NDI, 316, 345, 346, 348-350, 542-543
AQP3 (aquaporin 3), 540
AQP3 gene in NDI, 345-346
AQP4 (aquaporin 4), 540-541
AQP4 gene in NDI, 345-346
AQP5 (aquaporin 5), 541
AQP7 (aquaporin 7), 541
AQP8 (aquaporin 8), 541
AQP9 (aquaporin 9), 541
Aquaporin (AQP) mediated water flux, 533-550
and AQP inhibitors as diuretics, 544-546
MIP family and, *see* Major intrinsic protein/AQP family
Arachidonate metabolism, enzymes involved in, as NO targets, 219-220
Arginase-glomerulus activity, competitive pathways of L-arginine metabolism in, GN and, 280-281
L-Arginine
competitive pathways of metabolism of, in glomerulus-arginase activity, GN and, 280-281
see also L-Arginine, role of NO and, in renal function and structure in renal disease
L-Arginine, role of NO and, in renal function and structure in renal disease, 304-309
in diabetic nephropathy, 306-307
in glomerular diseases, 307
other effects of L-arginine, 307-308
in remnant kidney, 305-306
in ureteral obstruction, 304-305
Arginine-vasopressin (AVP), NDI and antidiuretic action of, in distal nephron, cellular physiology of, 345-346
Arrhythmias, cardiac, with congenital LQTS, K channels in, 444-446
Arteriosclerotic lesion formation, dietary K protection against, 478, 482, 484
AS, *see* Alport syndrome
AT_1 (angiotensin II receptor 1 subtype), hemodynamic effects of angiotensin II-NO interactions and, 244, 245, 248
AT_1 (angiotensin II receptor 1 subtype) gene, role of, in hypertension, 204
ATP6B1 gene in dRTA, 371
ATPase (adenosine triphosphatase), *see*
Autoantibodies, *see* Anti-DNA autoantibodies in lupus nephritis; Antigen(s) in lupus nephritis, autoantibodies and; Antiphospholipid autoantibodies; Nephritogenic autoantibodies in pathogenesis of lupus nephritis
Autoantigens in lupus nephritis, 39-41
including specifically cleaved proteins or proteins with role in apoptosis, 40-41
on surface of cells undergoing apoptosis, 39-40
see also Antigen(s) in lupus nephritis
Autoimmune diseases
cell surface binding to autoantibodies in, 53-54; *see also* Lupus nephritis
see also Autoimmune nephritis; NOS2, inhibition of, in organ-specific autoimmune disease
Autoimmune interstitial nephritis, NOS2 inhibition effects on, 289-290
Autoimmune nephritis
autoimmune interstitial nephritis, NOS2 inhibition effects on, 289-290
need for research on, 107
see also Lupus nephritis
Autoimmunity, *see* Autoimmunity in lupus nephritis; Lymphocyte tolerance to self-antigens, pathogenesis of autoimmunity and *entries beginning with term*: Autoimmune
Autoimmunity in lupus nephritis
genetics of, 14-17
role of apoptosis in, *see* Apoptosis, and autoimmunity in lupus nephritis
Autosomal dominant diabetes insipidus (NDI), 349
Autosomal dominant polycystic kidney disease (ADPKD), 313, 314, 316
genetic testing for, 322-325
molecular basis of, *see* Molecular genetics of ADPKD
see also Autosomal dominant polycystic kidney disease in women
Autosomal dominant polycystic kidney disease (ADPKD) in women, 123-132
clinical manifestations and management of, 124-126
diagnosis of, and genetic counseling for, 123-124
progression of, *see* Progression of ADPKD in women, pathophysiological factor(s) associated with
Autosomal dominant (type 1a) pseudohypoaldosteronism, 314, 376-377
Autosomal recessive diabetes insipidus (DI), 348-349
Autosomal recessive (type 1b) pseudohypoaldosteronism, 314, 376
AVP (arginine-vasopressin), antidiuretic action of, in distal nephron in NDI, cellular physiology of, 345-346
Azathioprine, low-dose steroids and, to prevent progression of advanced IgA glomerulonephritis, 169, 171
Azotemia, diuretic-induced, 557-558

B cells
ds-DNA B cell clones in lupus nephritis, LPJ-394 effects on, 72-73
see also Lymphocyte tolerance to self-antigens, pathogenesis of autoimmunity and
Bartter's syndromes (and Bartter's-like syndromes), 314, 367-370, 385
K channels and, 447-448

lessons from, on TAL cotransporter genes, 513
Basolateral membrane of tubular cells
citrate transport across, 196-197
K recycling across, K channels and, 460-461
Benign familial hematuria (BFH), 314, 354
Berger's disease, *see* Mesangial IgA glomerulonephritis, treatment preventing progression of
Beta (β) subunit of H,K-ATPase
colonic, molecular studies of, 410-411
renal, cDNA clones of, 434-436
BFH (benign familial hematuria), 314, 354
Bicarbonate, *see* Supplemental KCl and $KHCO_3$, effects of
Binding sites of amiloride within extracellular domains of ENaC, 528-529
Biochemical activity of NOS isoforms in kidney, 232-233
Biological target(s) of NO, 216, 219-223
in acute renal injury, 264
apoptosis as, 221-222
energy metabolism as, 220-221
enzymes involved in arachidonate metabolism as, 219-220
guanylate cyclase as, 219
methionine metabolism and alcohol metabolism as, 223
NO cytotoxicity and NO cell defense mechanisms, 222-223
NOS as, 219
receptors and signal amplification systems as, 220
transcription factors, DNA synthesis, and iron metabolism as, 221
Birth weight, and hypertension, 205-206
Blood pressure
dietary K effects on, 500-502
genes involved in control of, 201-202; *see also* Gene(s), hypertension
Bone measurement in osteoporotic ESRD women, 119-120
Braking phenomenon in chronic adaptation to diuretics, 585-586

Ca (calcium)
Na,Ca,K exchanger family of K transporters, 452
see also Ca metabolism, diuretic effects on; CaR; Hypercalcemia; Hypercalciuria, genetic; Hypercalciuric Bartter's syndrome
Ca (calcium) metabolism, diuretic effects on, 551-556
of carbonic anhydrase inhibitors, 551
of K^+-sparing diuretics, 555-556
of loop diuretics, 551-553
of thiazide diuretics, 553-555
Calcium, *see* Ca
Cancer
endometrial, in dialyzed ESRD women, 144
genetic testing for renal tumors, 325; *see also* Renal cell carcinoma; Wilms' tumor
risk of, with renal transplantation for lupus nephritis, 81
Candidate gene approach
to disease-gene identification, 316
to genetic hypertension and cardiorenal disease, 202-204
in idiopathic hypercalciuria, 385-386
CaR (calcium-sensing receptor), inherited disorders of, 370, 385
Carbonic anhydrase inhibitors, effects of, on Ca metabolism, 551
Cardiac arrhythmias with congenital LQTS, K channels in, 444-446
Cardiorenal disease, *see* Acquired hypertension and cardiorenal disease; Genetic hypertension and cardiorenal disease
Cardiorenal injury, *see* Salt sensitivity, cardiorenal injury, NO and, in hypertension
Cardiovascular disease with ADPKD, causes and management of, 124
Career choices, environment facilitation for men and women considering, 211-212
Career development for women, as WIN goal, 211
Cation(s)
nongastric pump, specificity of, 424-426
see also Cation channel(s) in OMCD; Cation-Cl family of K transporters
Cation channel(s) in OMCD, 472-475
electrophysiological properties of OMCD cells, 472
path clamp study of, 472-473
single, 473-475
Cation-Cl (chloride) family of K transporters, electroneural, 448-452
CCDs, *see* Cortical collecting ducts
CD40 ligand blockade in lupus nephritis therapy, 73-75
cDNA (complementary deoxyribonucleic acid) clones of renal H^+,K^+-ATPase, 431-436
of α-subunit, 432-434
of β-subunit, 434-436
Ceiling doses of diuretics, 589
Cell activation in lupus nephritis, cytokines in, 62-63
Cell adhesion in lupus nephritis, cytokines in, 61-62
Cell death, programmed, *see* Apoptosis
Cell defense mechanisms against NO cytotoxicity, 222-223
Cell differentiation, *see* Hensin pathway in intercalated cells
Cell proliferation, and progression of ADPKD, 126-127
Cell signaling by NO, 215-229
biological targets of NO and, *see* Biological target(s) of NO
NO reactivity and, 218-219
NOS isoforms and NO synthesis, 217-218
Cell surface
binding of, to autoantibodies in autoimmune diseases, 53-54
of cells undergoing apoptosis, lupus nephritis autoantigens on, 39-41
Cell surface antigen, nuclear localization of anti-DNA antibodies in lupus nephritis through interaction with ubiquitous, 52-53
Cell-type-specific polarity and targeting, hensin pathway in intercalated cells and, 416
Cellular actions of K, vasoprotective effects of dietary K and, 478-480
Cellular immunity, *see* B cells; Cellular immunity in lupus nephritis; Interstitial nephritis, T cells in; T cells
Cellular immunity in lupus nephritis, 177-180
macrophages and, 58-59, 177-180
T cells and, 178-180
Cellular physiology of AVP antidiuretic action in distal nephron in NDI, 345-346
Central lymphocyte tolerance to self-antigens, 25-26
Chemokines, *see* Renal cytokines and chemokines in pathogenesis of lupus nephritis
CHF (congestive heart failure), AQP2 and, 543
Chloride, *see* Cation family of K transporters; Cl channels;

Diuretics; Salt sensitivity, cardiorenal injury, NO and, in hypertension; Supplemental KCl and $KHCO_3$, effects of
Chronic adaptation to diuretics, 585-588
Chronic hypokalemia, $HK\alpha_2$ regulation in renal medulla by, 400-402
Chronic nitric oxide synthase (NOS) blockade, effects of, on renal function, 247-248
CIC-5 gene, hypercalciuria and, 384-385
Circulating immune complexes, glomerular deposition of, in lupus nephritis, 175
Cirrhosis
  AQP2 and, 543
  diuretics in, 575-578
Citrate transport across renal and intestinal membranes, 195-200
  across apical membrane of tubular cells, 195-196
  across basolateral membrane of tubular cells, 196-197
  cloning and characterization of Na-citrate transporters, 197-198
  regulation of, 197
Cl (chloride), *see* Cation-Cl family of K transporters; Cl channels; Diuretics; Na-K-2Cl; Salt sensitivity, cardiorenal injury, NO and, in hypertension; Supplemental KCl and $KHCO_3$, effects of
Cl (chloride) channels, *CIC-5* gene and, in hypercalciuria, 384-385
Classic Bartter's syndrome, 367-369
Cleaved proteins, autoantigens in lupus nephritis including specifically, 40-41
Clinical features and manifestations
  of ADPKD, 124-126
  of IgA nephropathy, 167
  of NDI, 344
Clinical implications
  of supplemental KCl and $KHCO_3$ effects, *see* Supplemental KCl and $KHCO_3$, effects of
  of two-hit model of ADPKD, 340-341
Clinical trials, controlled, of lupus nephritis therapy, 3
Clinical uses
  of loop diuretics, 552-553
  of thiazide diuretics, 555
Cloning
  of ds-DNA B cells in lupus nephritis, LPJ-394 effects of, 72-73
  functional and positional, disease-gene identification with, 316
  of pore-forming K channels, 441-442
  see also cDNA clones of renal H^+,K^+-ATPase
COL5A1 gene in NPS, 359
COLA4A3 gene
  in AS, 353
  in BFH, 354
COLA4A4 gene
  in AS, 353
  in BFH, 354
COLA4A5 gene in AS, 324-325, 353-354
COLA4A6 gene in AS, 353
Collecting ducts
  diuretics inhibiting NaCl transport in, 516-519
  microanatomy of, 189
  and organization of collecting duct system, 390-391
  see also Cation channel(s) in OMCD; Collecting ducts, adaptation of, to K^+ depletion; Cortical collecting ducts
Collecting ducts, adaptation of, to K^+ depletion, 390-396
  general features of, 393
  K handling along collecting duct in normokalemia and, 390-393
  molecular mechanisms responsible for K^+ depletion, 394
  molecular mechanisms responsible for K^+ reabsorption, 394-395
  structural changes induced by K^+ depletion, 395-396
Colonic H^+,K^+-ATPase (hydrogen, potassium-adenosine triphosphatase), 405-414
  molecular studies of, *see* Molecular studies of colonic H,K-ATPase
  physiological studies of, 406-408
Colony-stimulating factor, *see* Granulocyte macrophage colony-stimulating factor; Macrophage colony-stimulating factor
Combination diuretics for diuretic resistance, 590-593
Complementary deoxyribonucleic acid, *see* cDNA clones of renal H^+,K^+-ATPase
Complications
  of lupus nephritis conventional therapy, 67-68
  see also Metabolic and adverse effects of diuretics
Compromised pregnancy, GFR in, 135-137
Congenital long QT syndromes (LQTS), K channels in, 444-446
Congenital nephrogenic diabetes insipidus, *see* Nephrogenic diabetes insipidus
Congenital nephrosis, genetic testing for, 325
Congenital nephrotic syndrome, Finnish-type, 314, 355-356
Congestive heart failure (CHF), AQP2 and, 543
Connecting tubules, *see* Cortical collecting ducts, regulation of K^+ transport in maturing
Continuous diuretic infusions for diuretic resistance, 593-595
Controlled clinical trials of lupus nephritis therapy, 3
Convoluted tubules, distal thiazide diuretics inhibiting NaCl transport in, 513-516
Coronary artery thrombosis, dietary K protection against, 480-482
Coronary heart disease, dietary K effects on, and on mortality due to, 500-502
Cortical collecting ducts (CCDs)
  K channels in, 463-465
  see also Cortical collecting ducts, regulation of K^+ transport in maturing
Cortical collecting ducts (CCDs), regulation of K^+ transport in maturing, 156-163
  in intercalated cells, 162-163
  in principal cells, 158-162
Corticosteroids, osteoporosis in lupus nephritis due to, renal transplantation and, 81-82
Costimulatory molecules
  induction of, and autoimmunity, 28-29
  in lupus nephritis therapy, 68-69
Costimulatory pathways, T cell, cellular immunity in lupus nephritis and, 178-179
Cotransporter(s)
  Na-citrate, cloning and characterization of, 197-198
  Na-K-2Cl, in TAL, 507-509
  see also Cotransporter genes and proteins in NaCl transport

Cotransporter genes and proteins in NaCl transport, 507-517
in collecting duct, 516-517
in DCT, 513-514
in TAL, 507-513
Counseling, *see* Genetic counseling
Cox-2 (cyclooxygenase 2), NO interaction with, 259
Crypt cells, colonic H,K-ATPase distribution in, 407-408
Cryptic antigenic determinants, uncovering of, and autoimmunity, 29-30
CSF (colony-stimulating factor), *see* Granulocyte macrophage colony-stimulating factor; Macrophage colony-stimulating factor
CTLA4, failure of T cell inactivation mediated by, autoimmunity and, 29
Cyclooxygenase 2 (Cox-2), NO interaction with, 259
Cyclophosphamide, IgA glomerulonephritis progression prevented with, 169, 171
Cyclosporine A, IgA glomerulonephritis progression prevented with, 169-170
Cyst(s)
formation of, in ADPKD, mechanisms of, 336-338; *see also* Autosomal dominant polycystic kidney disease
see also Cystic liver disease with ADPKD
Cystic liver disease with ADPKD
causes and management of, 125-126
PKD1 gene mutations in, 339
Cystinuria, 314, 364-365
Cytochrome P-450 products, NO interaction with, 259
Cytokines (and cytokine receptor)
phenotypes of, in knockout mice, endogenous NO production and, 293
see also Renal cytokines and chemokines in pathogenesis of lupus nephritis
Cytotoxicity of NO
in acute renal injury, 264
cell defense mechanisms against, 222-223

DCT (distal convoluted tubules), thiazide diuretics inhibiting NaCl transport in, 513-516
DDS (Denys-Drash syndrome), 356-357
Death, *see* Apoptosis; Mortality
Degenerescence, neuronal, hyperexcitability and, K channels in, 446-447
Deletional mechanisms, peripheral lymphocyte tolerance to self-antigens and, 26
breakdown of, and induction of autoimmunity, 28
Dent's disease (X-linked nephrolithiasis), 314, 384-385
Denys-Drash syndrome (DDS), 356-357
Deoxyribonucleic acid, *see* DNA
Depletion, K^+, *see* Collecting ducts, adaptation of, to K^+ depletion
Development, *see* Renal development
Diabetes insipidus, *see* Nephrogenic diabetes insipidus
Diabetic nephropathy
need for research on, 106
renal function and structure in, role of L-Arginine and NO in, 306-307
Diagnosis
of ADPKD in women, 123-124
prenatal and presymptomatic, ethical issues in, 322-323
see also specific conditions
Dialysis for ESRD women, 140-147
choice of dialysis modality, 142
epidemiological factors in, 140-141
and medical issues affecting women, 142-145
survival and, 140-142
Diet, maternal, during pregnancy, hypertension and cardiorenal disease and, 206-208
Dietary K (potassium)
effects of, on blood pressure, coronary heart disease, and coronary heart disease-associated death, 500-502
see also Supplemental K; Vascular protective effects of dietary K
Diffuse mesangial sclerosis (DMS), DDS and, 357
Dipyridamole, IgA glomerulonephritis progression prevented with, 169, 171
Direct mutation testing, characteristics of, 321
Discovery
of *PKD1* gene, 328
of *PKD2* gene, 334
Disease activity and mechanisms
of ESRD, renal transplantation and, 78
of lupus nephritis, 20-22; *see also* Apoptosis, and autoimmunity in lupus nephritis; Cellular immunity in lupus nephritis; Humoral immunity in lupus nephritis; Lymphocyte tolerance to self-antigens in lupus nephritis; Nephritogenicity in lupus nephritis; Renal cytokines and chemokines in pathogenesis of lupus nephritis
see also specific conditions
Disease-gene identification, 315-317
genetic testing and, 316-317; *see also* Genetic testing for renal disease
strategies for, 316
Disomy, uniparental, and inherited renal disease, 315
Distal convoluted tubule (DCT), thiazide diuretics inhibiting NaCl transport in, 513-516
Distal nephron in NDI, cellular physiology of antidiuretic action of AVP in, 345-346
Distal renal tubular acidosis (dRTA), 188-194, 314, 370-371
and dRTA syndromes, 189-193
renal acid excretion by proton ATPase and, 189; *see also* H^+,ATPase; H,K-ATPase
Diuretic resistance
causes of, 588-589
see also Adaptation to diuretics; Therapy of diuretic resistance
Diuretics
antidiuretic action of AVP in distal nephron in NDI, 345-346
in cirrhosis, 575-578
introduction to, 503
in nephrotic syndrome, 575, 578-580
see also Aquaporin mediated water flux; Ca metabolism, diuretic effects on; Diuretic resistance; Hypertension, diuretics in; Metabolic and adverse effects of diuretics; Molecular mechanisms of diuretics inhibiting NaCl transport
DMS (diffuse mesangial sclerosis), DDS and, 357
DNA (deoxyribonucleic acid)
synthesis of, as NO target, 221
see also Anti-DNA antibodies; Anti-DNA autoantibodies in lupus nephritis; cDNA clones of renal H^+,K^+-ATPase; DNA-histone complexes
DNA (deoxyribonucleic acid)-histone complexes due to inter-

nucleosomal cleavage during apoptosis, anti-DNA autoantibodies against, in lupus nephritis, 38-39
Doses
high diuretic, for diuretic resistance, 589-590
low, *see* Low doses
Doxycycline, effects of, on hematuria in IgA glomerulonephritis, 168
dRTA, *see* Distal renal tubular acidosis
Drug reactions, adverse, to diuretics, 565
ds-DNA (deoxyribonucleic acid) B cell clones in lupus nephritis, LPJ-394 effects of, 72-73
Duality of NO, *see* Acute renal injury, NO in

ECM, *see* Extracellular matrix
ECV (extracellular volume) depletion, diuretic-induced, 557-558
EDRF (endothelium-derived relaxing factor), *see* Nitric oxide
Effector mechanisms
in lupus nephritis, 20-22
see also Effector T cells, nephritogenic
Effector T cells, nephritogenic
in interstitial nephritis, 184-186
in lupus nephritis, 178
Electrical potential, negative tubular cell, role of K channels in maintenance of, 458-459
Electrochemical gradient in principal cells of CCDs, developmental regulation of K^+ transport and, 158
Electroneural cation-Cl (chloride) family of K transporters, 448-452
Electrophysiological properties of OMCD cells, cation channels and, 472
ENaC, *see* Epithelial Na channel, genetic disorder(s) of; Epithelial Na channel, molecular mechanisms of amiloride effects on; Epithelial Na channel genes
Encephalomyelitis, allergic, NOS2 inhibition effects on, 290-292
Endogenous nitric oxide (NO), as antiproliferative agent for T cells, 292-294
Endogenous NOS2 (inducible nitric oxide synthase; iNOS) regulators in sepsis, 275-276
Endometrial cancer in dialyzed ESRD women, 144
Endothelial cell-neutrophil adhesion in acute renal injury, NO and, 264-265
Endothelial nitric oxide synthase, *see* NOS3
Endothelium-derived relaxing factor, *see* Nitric oxide
Endotoxic glomerular injury, NO role in, 282
End-stage renal disease, *see* End-stage renal disease in women; Renal transplantation for lupus nephritis-induced ESRD
End-stage renal disease (ESRD) in women
need for research on, 106
see also Dialysis for ESRD women; Osteoporosis in ESRD women
Energy metabolism, as NO target, 220-221
eNOS (endothelial nitric oxide synthase), *see* NOS3
Environment for women in nephrology, improving
strategic interventions for, 96-97
as WIN goal, 211-212
Environmental factors
in acquired hypertension, 205-208
in lupus nephritis, 17-18

Enzymes
involved in arachidonate metabolism, as NO targets, 219-220
source of NO, NO action related to, 269-270
Epidemiology
of dialyzed ESRD women, 140-141
of intrauterine origins of hypertension and cardiorenal disease, 205-206
see also specific conditions
Epithelial cells, renal H,K pumps in, sorting of, 423-424
Epithelial hypertrophy (and hyperplasia), and chronic adaptation to diuretics, 586-588
Epithelial Na channel (ENaC), genetic disorder(s) of, 374-380
AME syndrome as, *see* Apparent mineralocorticoid excess syndrome
autosomal dominant pseudohypoaldosteronism as, 314, 376-377
autosomal recessive pseudohypoaldosteronism as, 314, 376
GRA as, *see* Glucocorticoid-remediable aldosteronism
Liddle's syndrome as, *see* Liddle syndrome
Epithelial Na channel (ENaC), molecular mechanisms of amiloride effects on, 524-532
amiloride-ENaC pore interaction, 527-528
binding sites of amiloride within ENaC extracellular domains, 528-529
and ENaC as site of amiloride action, 524-527
Epithelial Na channel (ENaC) genes, 516-519
in collecting duct NaCl transport, 516-517
mutations of, 518-519
see also Epithelial Na channel, genetic disorder(s) of
Epithelial polarity, defective of, and progression of ADPKD, 128
Epithelial wound healing, NO in, 265
Epithelium, *see* Terminal differentiation in epithelia, hensin and *and entries beginning with term*: Epithelial
Epitope spreading, and autoimmunity development, 43
Equity of access to care for women, 107
ESRD (end-stage renal disease), *see* End-stage renal disease in women; Renal transplantation for lupus nephritis-induced ESRD
Ethical issues in genetic testing, 322-323
Experimental models
of acute glomerulonephritis, NO role in, 283
of ADPKD, 338-340
of allergic encephalomyelitis, 290-292
of genetic hypertension, 205
of salt-sensitive hypertension, 299-302
see also Experimental models of lupus nephritis; Knockout *and specific studies*
Experimental models of lupus nephritis, 12-24
conclusions on, 22
effector mechanisms in, 20-22
environmental factors in, 17-18
genetic basis of autoimmunity in, 14-17
immune interactions in, 18-20
NO role in, 282-283
types of, 12-14
Extracellular calcium-sensing receptor (CaR), inherited disorders of, 370
Extracellular domains of ENaC, binding sites of amiloride within, 528-529

Extracellular matrix (ECM)
abnormalities of, and progression of ADPKD, 129
hensin localization in, 417-418
Extracellular volume (ECV), diuretic-induced depletion of, 557-558

Fabry disease, 358-359
Familial hematuria, benign, 314, 354
Familial hyperuricosuria, as risk factor for nephrolithiasis, 381-383
Familial steroid-resistant nephrotic syndrome, 356
Fas gene, role of, in lymphocyte tolerance to self-antigens in lupus nephritis, 42
Fertility of ADPKD women, 126
Fetal *PKD-1* gene, persistent expression of, and progression of ADPKD, 129
Fetal renal development, RAS in, 148-150
Fibrosis in lupus nephritis, role of cytokines in, 63
Finnish-type congenital nephrotic syndrome (NPHS1), 314, 355-356
Fish oils, IgA glomerulonephritis progression prevented with, 170
Fluid and electrolyte abnormality(ies), diuretic-induced, 557-562
alkalosis and acidosis as, 562
ECV depletion and azotemia as, 557-558
hypercalcemia as, 561-562
hyperkalemia and hypomagnesemia as, 561
hypokalemia as, 559-561
hyponatremia as, 558-559
Fluid secretion, and progression of ADPKD, 127-128
Frasier syndrome, 356, 358
Free radicals, dietary K effects on formation of, 478-479
Functional cloning, disease-gene identification with, 316
Functional data on activity of NOS isoforms in kidney, 232-233
Functional properties of renal H,K pumps, 422-423

Gammaglobulin (IgG), intravenous, IgA glomerulonephritis progression prevented with, 171
Gene(s)
blood pressure control, 201-202; *see also* Gene(s), hypertension
transporter, *see* Cotransporter genes and proteins in NaCl transport
see also specific genes
Gene(s), hypertension, 201-205
RAS, 201-204
single gene abnormalities in Mendelian forms of hypertension, 204-205
General transport properties of collecting duct subsegments, 391
Genetic analysis
of *PKD1* gene, 328-332
of *PKD2* gene, 334
Genetic counseling
for NDI, 349
of women with ADPKD, 123-124
Genetic diseases
K channels in, 444-448
see also Genetic diseases, renal

Genetic diseases, renal
introduction to, 311
see also Autosomal dominant polycystic kidney disease; Epithelial Na channel, genetic disorder(s) of; Genetic hypertension and cardiorenal disease; Genetic testing for renal disease; Genetics of renal disease; Glomerular disease, inherited; Nephrogenic diabetes insipidus; Nephrolithiasis, risk factor(s) for; Tubular transport disorder(s), inherited
Genetic heterogeneity, testing complicated by, 321-322
Genetic hypercalciuria, *see* Hypercalciuria, genetic
Genetic hypertension, *see* Epithelial Na channel, genetic disorder(s) of; Genetic hypertension and cardiorenal disease
Genetic hypertension and cardiorenal disease, 201-205, 208-210
candidate gene approach to, 202-204
experimental models of, 205
and genes involved in blood pressure control, 201-202
and Mendelian forms of hypertension, 204-205
Genetic testing for renal disease, 319-326
for ADPKD, 322-325
approaches to, 319-321
for AS, 324-325
for congenital nephrosis, 325
disease-gene identification and, 316-317
ethical issues in, 322-323
for renal tumors, 325
technology transfer in, 323-324
test interpretation, 321-322
Genetics
of systemic autoimmunity in lupus nephritis, 14-17
see also DNA; Gene(s); Genetics of renal disease; Genomic imprinting; Knockout; Mutations; Nitric oxide synthase isoforms, gene products of; Phenotypes *entries beginning with terms*: Congenital, Genetic, Molecular *specific genes and conditions*
Genetics of renal disease, 312-318
disease-gene identification and, *see* Disease-gene identification
future considerations in, 317
of NDI, 346
see also Inheritance of renal disease
Genomic imprinting, and renal disease, 315
Gestational glomerular filtration rate (GFR), 133-139
in compromised pregnancy, 135-137
in normal pregnancy, 133-135
possible reasons for increase in, 137-138
GFR, *see* Glomerular filtration rate
Girls, ESRD adolescent, medical issues affecting dialyzed, 174-175
Gitelman syndrome, 314, 367, 369-370, 385
NaCl transport in DCT and lessons learned from, 515-516
Glomerular antigens, direct binding of autoantibodies to, in lupus nephritis, 50-52
Glomerular deposition of immune complexes in lupus nephritis
circulating immune complexes, 175
in situ formation of immune complexes and, 174-175
Glomerular disease
renal function and structure in, role of L-arginine and NO in, 307
see also Glomerular disease, inherited

Glomerular disease, inherited, 353-363
AS as, *see* Alport syndrome
BFH as, 314, 354
DDS as, 356-357
Fabry disease as, 358-359
Frasier syndrome as, 356, 358
nephrotic syndrome as, *see* Nephrotic syndrome
NPS as, 359
Glomerular filtration rate (GFR)
NO in regulation of, 242-244
see also Gestational glomerular filtration rate
Glomerular injury, endotoxic, NO role in, 282
Glomerulonephritis, *see* Glomerulonephritis, NO in; Lupus nephritis; Mesangial IgA glomerulonephritis, treatment preventing progression of
Glomerulonephritis (GN), NO in, 277-287
competitive pathways of L-arginine metabolism in glomerulus-arginase activity in, 280-281
in endotoxic glomerular injury, 282
in experimental acute GN, 283
in immune-mediated diseases, 281-282
in murine SLE, 282-283
NO actions in GN, 281
NO production in GN, 277
NOS2 in, *see* NOS2 in GN
and NOS2 gene knockout, 283-284
NOS3 in, 277-278, 285
sources of NO in, 280
Glomerulus-arginase activity, competitive pathways of L-arginine metabolism in, GN and, 280-281
Glucocorticoid-remediable (-responsive) aldosteronism (GRA), 316
described, 378
Mendelian form of hypertension in, 204
Glutamate/neutral amino acid family of K transporters, Na,K-dependent, 451-452
GM-CSF (granulocyte macrophage colony-stimulating factor), role of, in lupus nephritis, 59-60, 177, 178
GN, *see* Glomerulonephritis, NO in; Lupus nephritis; Mesangial IgA glomerulonephritis, treatment preventing progression of
Gonadal dysfunction, as risk factor for osteoporosis in ESRD, 117-119
GRA, *see* Glucocorticoid-responsive aldosteronism
Graft survival, short-term, in renal transplantation for lupus nephritis-induced ESRD, 77-78
Granulocyte macrophage colony-stimulating factor (GM-CSF), role of, in lupus nephritis, 59-60, 177, 178
Growth factors
autoimmunity and failure of immunoregulation mediated by TGF-β1, 30
see also Hematopoietic growth factors in lupus nephritis
Guanylate cyclase, as NO target, 219

H^+-ATPase (hydrogen-adenosine triphosphatase)
in dRTA, 189-193
kAE1 and plasticity of polarity of, hensin pathway in intercalated cells and, 415-416
see also H,K-ATPase
HCO_3 (bicarbonate), *see* Supplemental KCl and $KHCO_3$, effects of
Health care team, interdisciplinary nephrology, need to include NPCs in, 102-103
Health (medical) issues, women's
affecting dialyzed ESRD women, 142-145
see also Research in women's health issues
Health maintenance in dialyzed ESRD women, 145
Heart disease, coronary, dietary effects on, and on death due to, 500-502
Heart failure, congestive, AQP2 and, 543
Hematopoietic growth factors in lupus nephritis, 57-60
GM-CSF as, 59-60, 177, 178
M-CSF as, 58-59, 177-178
Hematuria
benign familial, 314, 354
preventing progression of mesangial IgA glomerulonephritis with treatment to reduce, 167-168
Hemodynamics, *see* Blood pressure; Glomerular filtration rate; Renal hemodynamics, role of NO in
Henle's loop, *see* Thick ascending limb of Henle's loop
Hensin pathway in intercalated cells, 415-420
cell-type-specific targeting and, 416
and hensin properties, 416-417
localization of hensin in ECM, 417-418
polarity and, *see* Polarity of intercalated cells, hensin pathway and
terminal differentiation in epithelia and, *see* Terminal differentiation in epithelia, hensin and
Heterogeneity, genetic, testing complicated by, 321-322
High dose of diuretics for diuretic resistance, 589-590
Histochemical activity of NOS isoforms in kidney, 232-233
Histone, anti-DNA autoantibodies against DNA-histone complexes due to internucleosomal cleavage during apoptosis, lupus nephritis and, 38-39
History of women's role in nephrology, 89-94
$HK\alpha_2$, regulation of, in renal medulla by chronic hypokalemia, 400-402
H (and H^+),K (and K^+)-ATPase (hydrogen, potassium-adenosine triphosphatase), 189, 441
see also Colonic H^+,K^+-ATPase; Nongastric H^+,K^+-ATPase
H,K (hydrogen, potassium) pumps, renal, 189
functional properties of, 422-423
regulation of, 426-428
sorting of, in epithelial cells, 423-424
see also Renal H^+,K^+-ATPase
Humoral immunity in lupus nephritis, 173-177
immunosuppression and, 68-69
see also Immune deposits in lupus nephritis; Nephritogenic autoantibodies in pathogenesis of lupus nephritis
Hypercalcemia, diuretic-induced, 561-562
Hypercalciuria, genetic, 381
Cl channels, *CIC-5* gene and, 384-385
inheritance of, 383-384
linkage studies of, 386
other candidate genes in idiopathic hypercalciuria, 385-386
Hypercalciuric Bartter's syndrome, antenatal, 367-369
Hyperexcitability, neuronal degenerescence and, K channels in, 446-447
Hyperglycemia, diuretic-induced, 563
Hyperinsulinemic hypoglycemia of infancy, K channels in, 447
Hyperkalemia, diuretic-induced, 561

Hyperlipidemia, diuretic-induced, 563-564
Hyperoxaluria, primary, 381, 382
Hyperprostaglandin E (antenatal hypercalciuric Bartter's) syndrome, 367-369
Hypertension
  with ADPKD, causes and management of, 124-125
  genetic, *see* Epithelial Na channel, genetic disorder(s) of; Genetic hypertension and cardiorenal disease
  in mesangial IgA glomerulonephritis, control of, 170
  supplemental K effects on, 494-499
  supplemental KCl with $KHCO_3$ effects on, 488-489
  see also Acquired hypertension and cardiorenal disease; Hypertension, diuretics in; Salt sensitivity, cardiorenal injury, NO and, in hypertension
Hypertension, diuretics in, 569-574
  in low doses, effectiveness of, 569-570
  need for diuretic effect in hypertension and, 570-571
  overall need for diuretics in, 571-573
Hypertrophy (and hyperplasia), epithelial, and chronic adaptation to diuretics, 586-588
Hyperuricemia, diuretic-induced, 563-564
Hyperuricosuria, familial, as risk factor for nephrolithiasis, 381-383
Hypoglycemia, hyperinsulinemic, of infancy, K channels in, 447
Hypokalemia
  chronic, $HK\alpha_2$ regulation in renal medulla by, 400-402
  diuretic-induced, 559-561
Hypomagnesemia, diuretic-induced, 561
Hyponatremia, diuretic-induced, 558-559
Hypophosphatemic rickets (vitamin D-resistant rickets) as, 314, 365-367

ICAs (intracranial aneurysms) with ADPKD, causes and management of, 125
IFN-γ (interferon-γ), and cell adhesion in lupus nephritis, 62
IgA glomerulonephritis, *see* Mesangial IgA glomerulonephritis, treatment preventing progression of
IgG (gammaglobulin), intravenous, IgA glomerulonephritis progression prevented with, 171
Ignorance mechanism, peripheral lymphocyte tolerance to self-antigens and, 27-29
  breakdown of, and induction of autoimmunity, 28-29
IL-1 (interleukin-1), and cell adhesion in lupus nephritis, 62
L-N^6-(Iminoethyl)lysine (L-NIL), NOS2 inhibition with, 289-291
  in allergic encephalomyelitis, 290, 291
  in autoimmune interstitial nephritis, 289-290
Immediate adaptation to diuretics, 581-583
Immune complexes, *see* Immune deposits in lupus nephritis
Immune deposits in lupus nephritis, 52
  glomerular, *see* Glomerular deposition of immune complexes in lupus nephritis
  and mechanisms of autoantibody pathogenesis, 175-177
  see also Immune deposits in lupus nephritis, location of
Immune deposits in lupus nephritis, location of, 49-51
  antigenic specificity influencing, 50-51
  nephritogenic autoantibodies and differences in location of, 49-50
Immune interactions in lupus nephritis, 18-20
Immune-mediated diseases, NO role in, 281-282
Immunity, *see* Autoimmunity in lupus nephritis; B cells; Cellular immunity in lupus nephritis; Humoral immunity in lupus nephritis; T cells *entries beginning with term*: Immune *and element*: Immun-
Immunization with apoptotic cells inducing aPL autoantibodies, 41
Immunoglobulin A glomerulonephritis, *see* Mesangial IgA glomerulonephritis, treatment preventing progression of
Immunoregulation
  breakdown of, and pathogenesis of autoimmunity, 30
  see also Immunoregulation, NO and
Immunoregulation, NO and, 288-295
  and NO as endogenous antiproliferative agent for T cells, 292-294
  NOS2 inhibition and, *see* NOS2, inhibition of, in organ-specific autoimmune disease
Immunosuppression
  NO-induced, 293-294
  see also Immunosuppressive therapy of lupus nephritis
Immunosuppressive therapy of lupus nephritis, 3-9
  anticipated directions in, 8-9; *see also* Immunosuppressive therapy of lupus nephritis, novel approach to
  complications of, 67-68
  controlled clinical trials of, 3
  of lupus membranous nephropathy, 8
  of proliferative lupus nephritis, 6-7
  race and outcome of, 3-4
  and relapse, 5-6
  and remission, 5
Immunosuppressive therapy of lupus nephritis, novel approach to, 67-76
  anti-DNA autoantibodies and, 69-72
  with CD40 ligand blockade, 73-75
  and complications of conventional therapy, 67-68
  costimulation, humoral immunity and, 68-69
  with LPJ-394, 72-73
Impotence, diuretic-induced, 564
Inducible nitric oxide synthase, *see* NOS2
Infiltrating leukocytes in lupus nephritis, antigen specificity of, 184
Inflammatory leukocytes in lupus nephritis, cytokines in recruitment of, 60-61
Inflammatory phenotype in lupus nephritis, antigen specificity influencing, 50-51
Inheritance, *see* Genetics; Inheritance of renal disease
Inheritance of renal disease
  of hypercalciuria, 383-384
  patterns of, 312-315; *see also* Mendelian pattern of inheritance
  see also Genetics of renal disease
iNOS (inducible nitric oxide synthase), *see* NOS2
In situ immune complex formation, and glomerular immune deposition in lupus nephritis, 174-175
Insulin-like growth factor-1, role of, in renal morphological alterations due to K^+ depletion, 396-397
Intercalated cells
  of CCDs, developmental regulation of K^+ transport in, 158-162
  see also Hensin pathway in intercalated cells
Interdisciplinary nephrology health care team, need to include NPCs in, 102-103

Interferon-γ (IFN-γ), and cell adhesion in lupus nephritis, 62
Interleukin-1 (IL-1), and cell adhesion in lupus nephritis, 62
Internucleosomal cleavage during apoptosis, anti-DNA autoantibodies against DNA-histone complexes due to, lupus nephritis and, 38-39
Interpretation of genetic tests, 321-322
Interstitial nephritis
  autoimmune, NOS2 inhibition effects on, 289-290
  diuretic-induced, 565
  see also Interstitial nephritis, T cells in
Interstitial nephritis, T cells in, 182-187
  antigen specificity of infiltrating T cells, 184
  nephritogenic, 184-186
  priming of, 182-184
Intestinal membranes, *see* Citrate transport across renal and intestinal membranes
Intracranial aneurysms (ICAs) with ADPKD, causes and management of, 125
Intrarenal nitric oxide (NO), role of, in hypertension, 296-297
Intrauterine origins of hypertension and cardiorenal disease, 205-206
Intravenous gammaglobulin (IgG), IgA glomerulonephritis progression prevented with, 171
Ions
  secretion of, and progression of ADPKD, 127-128
  see also specific ions
Iron metabolism, as NO target, 221
Ischemia, renal, in acute renal injury, effects of NOS2 gene knockout on, 268-269
Isoforms of NOS, *see* NOS1; NOS2; NOS3

K and K^+ (potassium)
  introduction to, 389
  regulation of, vascular protective effects of dietary K and, 477-478
  see also Cation channel(s) in OMCD; Collecting ducts, adaptation of, to K^+ depletion; Dietary K; Hensin pathway in intercalated cells; Hyperkalemia; Hypokalemia; K-ATPase; K channels; K-sparing diuretics; K transporters; Maturing kidney, regulation of K^+ transport in; Na-K-2Cl cotransporters; Nongastric H^+,K^+-ATPase
K (and K^+)-ATPase (potassium-adenosine triphosphatase), 438-441
  activities of, 402-403
  see also H^+,K^+-ATPase; Na^+,K^+-ATPase; Nongastric H^+,K^+-ATPase
K (and K^+) (potassium) channels, 441-448
  ancillary subunits of, and proteins associated with, 442-444
  cloned pore-forming, 441-442
  in genetic diseases, 444-448
  renal, *see* Renal K channels
  secretory TAL, 509-512
K (and K^+) (potassium)-sparing diuretics, 516
  effects of, on Ca metabolism, 555-556
  see also Amiloride
K (and K^+) (potassium) transporters, 448-452
  electroneural cation-Cl family of, 448-452
  Na,Ca,K exchanger family of, 452
  Na,K-dependent glutamate/neutral amino acid family of, 451-452
kAE1 (kidney form of band 3 anion exchanger), plasticity of H^+-ATPase polarity and, and hensin pathway in intercalated cells, 415-416
KCl (potassium chloride), *see* Supplemental KCl and $KHCO_3$, effects of
$KHCO_3$, *see* Supplemental KCl and $KHCO_3$, effects of
Kidney form of band 3 anion exchanger (kAE1), plasticity of H^+-ATPase polarity and, and hensin pathway in intercalated cells, 415-416
Kidney stones, *see* Nephrolithiasis
Knockout
  cytokine and cytokine receptor, and relationship of phenotypes to endogenous NO production, 293
  NOS1 gene, in acute renal injury, 268
  see also Knockout, *NOS2* gene
Knockout, *NOS2* gene
  in acute renal injury, 268-269
  in GN, 283-284

Leukocytes
  inflammatory, in lupus nephritis, cytokines in recruitment of, 60-61
  see also B cells; Lymphocyte tolerance to self-antigens, pathogenesis of autoimmunity and; Macrophage(s); T cells
Liddle syndrome, 314
  Mendelian form of hypertension in, 204-205
Linkage-based testing
  in blood pressure assessment, 202
  characteristics of, 320-321
  of hypercalciuria, 386
Liver disease, *see* Cystic liver disease with ADPKD
Living-related donors for renal transplantation in lupus nephritis-induced ESRD, 78
LMX1B gene in NPS, 359
Long QT syndromes (LQTS), congenital, K channels in, 444-446
Long-term morbidity and mortality with renal transplantation for lupus nephritis-induced ESRD, risk factors for, 79-82
Long-term renal effects of pregnancy, *see* Maternal renal function, long-term renal effects of pregnancy and
Loop diuretics
  clinical uses of, 551-553
  effects of, on Ca metabolism, 551-553
  see also Loop diuretics, TAL NaCl transport inhibited by
Loop diuretics, TAL NaCl transport inhibited by, 504-513
  consequences of, 512-513
  cotransporter genes and proteins in, 507-513
  and lessons from Bartter's syndrome, 513
  model of NaCl transport, 505-507
  targets of action of, 512
Low doses
  of diuretics for hypertension, effectiveness of, 569-570
  of steroids with azathioprine to prevent progression of advanced IgA glomerulonephritis, 169, 171
LPJ-394, effects of, on ds-DNA B cell clones in lupus nephritis, 72-73
LQTS (long QT syndromes), congenital, K channels in, 444-446
Lupus membranous nephropathy, 7-8
  immunosuppressive therapy of, 8
  natural history of, 7-8

Lupus nephritis
introduction to, 1
need for research on, 107
pathogenesis and disease mechanisms of, 20-22; *see also* Apoptosis, and autoimmunity in lupus nephritis; Cellular immunity in lupus nephritis; Humoral immunity in lupus nephritis; Lymphocyte tolerance to self-antigens in lupus nephritis; Nephritogenicity in lupus nephritis; Renal cytokines and chemokines in pathogenesis of lupus nephritis
see also Experimental models of lupus nephritis; Immunosuppressive therapy of lupus nephritis; Natural history of lupus nephritis; Renal transplantation for lupus nephritis-induced ESRD
Lymphocyte tolerance to self-antigens, pathogenesis of autoimmunity and, 25-33
central, 25-26
conclusion on, 30-31
peripheral, 26-28; *see also* Peripheral lymphocyte tolerance to self-antigens
see also Lymphocyte tolerance to self-antigens in lupus nephritis
Lymphocyte tolerance to self-antigens in lupus nephritis, 35-37
to apoptotic self-antigen, lupus as breakdown in, 42; *see also* Peripheral lymphocyte tolerance to self-antigens, breakdown of
role of *Fas* gene in, 36-37

Macrophage(s), and cellular immunity in lupus nephritis, 58-59, 177-178
Macrophage colony-stimulating factor (M-CSF; CSF-1), role of, in lupus nephritis, 58-59, 177-178
Macula densa, nNOS regulation of, 257-258
Major histocompatibility complex (MHC) class II, lupus dependence on, 43
Major intrinsic protein (MIP)/AQP family
AQP0 in, 536
AQP1/CHIP 28, 536-538
AQP2, *see* AQP2
AQP3, 540
AQP4, 540-541
AQP5, AQP7, AQP8, AQP9, 541
renal disease and, 541-542
Managerial positions, women in, 109-114
Maternal diet during pregnancy, hypertension and cardiorenal disease and, 206-208
Maternal renal function, long-term renal effects of pregnancy and, 135-137
compromised, 136-137
normal, 135
Maturing kidney, regulation of K^+ transport in, 155-165
in CCDs, *see* Cortical collecting ducts, regulation of K^+ transport in maturing
overall K^+ handling, 155-156
summary on, 163
in TALH, 156, 157
MCP-1 (monocyte chemoattractant protein-1) in lupus nephritis, 60-61
M-CSF (CSF-1; macrophage colony-stimulating factor) in lupus nephritis, 58-59, 177-178
Medical care, medicine and, in new millennium, thoughts about, 598-602
Medical issues, *see* Health issues, women's
Medulla, renal, $HK\alpha_2$ regulation by chronic hypokalemia in, 400-402
Medullary collecting duct, *see* Cation channel(s) in OMCD
Mendelian pattern of inheritance
of hypertension, 204-205
of renal disease, 312-313
Mesangial IgA (immunoglobulin A) glomerulonephritis, treatment preventing progression of, 166-172
of advanced disease, 170-171
with hematuria reduction, 167-168
with proteinuria reduction, 169-170
Mesangial sclerosis, diffuse, DDS and, 357
Metabolicacidosis, diuretic-induced, 562
Metabolic and adverse effects of diuretics, 557-568
allergy as, 564-565
fluid and electrolyte abnormalities as, *see* Fluid and electrolyte abnormality(ies), diuretic-induced
impotence and ototoxicity as, 564
interstitial nephritis and adverse drug reactions as, 565
metabolic abnormalities, 563-564
risks of diuretics in pregnancy and in newborns, 564
Metabolic alkalosis, diuretic-induced, 562
Methionine metabolism, as NO target, 223
MHC (major histocompatibility complex) class II, lupus dependence on, 43
Microanatomy of collecting ducts, 189
Mimicry, antigenic molecular, and autoimmunity, 29
Mineralocorticoids, disorders of ENaC regulation by, ENaC disorders due to, 376-378
Minorities, need to attract women and, to nephrology, 101-102
MIP, *see* Major intrinsic protein/AQP family
Mitochondrial inheritance of renal disease, 315
Mitogen-induced T-cell proliferation, endogenous NO inhibiting, 292-293
Molecular genetics
of hypertension development, 202
see also Molecular genetics of ADPKD
Molecular genetics of ADPKD, 327-343
ADPKD genes and, *see*: *PKD1* gene in ADPKD; *PKD2* gene in ADPKD
and ADPKD pathways, 335-336
animal models of, 338-340
clinical implications of two-hit model of, 340-341
mechanism of cyst formation in, 336-338
Molecular identification of renal H^+,K^+-ATPase, 431-437
Molecular mechanisms
responsible for K^+ depletion, 394
responsible for K^+ reabsorption in collecting ducts, 394-395
see also Molecular mechanisms of diuretics inhibiting NaCl transport
Molecular mechanisms of diuretics inhibiting NaCl transport, 504-523
in collecting ducts, 516-519
of loop diuretics, *see* Loop diuretics, TAL NaCl transport inhibited by
of thiazide diuretics, on DCT NaCl transport, 513-516
see also Epithelial Na channel, molecular mechanisms of amiloride effects on
Molecular mimicry, antigenic, and autoimmunity, 29
Molecular structure of renal K channels, 465-468

Molecular studies of colonic H,K-ATPase, 409-413
expression studies of, 411-412
regulation studies of, 412-413
of α subunit, 409
of β subunit, 410-411
Monocyte chemoattractant protein-1 (MCP-1) in lupus nephritis, 60-61
Morbidity
long-term, with renal transplantation for lupus nephritis-induced ESRD, risk factors for, 79-82
see also AQP2 in pathophysiological states *entries beginning with term*: Disease *and specific conditions*
Morphological alterations, renal, due to K^+ depletion, 395
Mortality
due to coronary heart disease, dietary K effects on, 500-502
long-term, with renal transplantation for lupus nephritis-induced ESRD, risk factors for, 79-82
see also specific conditions
Mutations
ENaC NaCl cotransport gene, 518-519
see specific genes and conditions

Na (and Na^+) (sodium)
role of NO in excretion of, 247
transepithelial voltage of CCD principal cells and absorption of, developmental regulation of K^+ transport and, 158-159
see also Diuretics; Epithelial Na channel, genetic disorder(s) of; Na,Ca,K exchangers; Na-citrate cotransporters; Na^+,K^+-ATPase; Na-K-2Cl cotransporters; Na,K-dependent glutamate/neutral amino acid family of K transporters; Salt sensitivity, cardiorenal injury, NO and, in hypertension
Na,Ca,K (sodium, calcium, potassium) exchangers, 452
Na (sodium)-citrate cotransporters, cloning and characterization of, 197-198
NaCl, *see* Diuretics; Salt sensitivity, cardiorenal injury, NO and, in hypertension
Nail-patella syndrome (NPS), 359
Na,K (Na^+,K^+)-ATPase (sodium, potassium-adenosine triphosphatase), 439-441
activity of, and K^+ concentration in principal cells of CCDs, developmental regulation of K^+ transport and, 159-160
in dRTA, 189-193
Na-K-2Cl (sodium-potassium-chloride) cotransporters, TAL, 507-509
Na,K (sodium, potassium)-dependent glutamate/neutral amino acid family of K transporters, 451-452
National Institutes of Health, *see* Research in women's health issues
Natural history of lupus nephritis, 2-11
of lupus membranous nephropathy, 7-8
and prognosis, 4-5
of proliferative lupus nephritis, 2-3
therapy and, *see* Immunosuppressive therapy of lupus nephritis
NDI, *see* Nephrogenic diabetes insipidus
Need(s) in nephrology, 98-104
attracting trainees as, 99-100
attracting women and minorities as, 101-102
for nephrologists to reflect renal patients' population, 100-101
for NPCs to be included in interdisciplinary nephrology health care team, 102-103
Negative electrical potential of tubular cells, role of K channels in maintenance of, 458-459
Neointimal lesion formation, dietary K protection against, 478, 482-485
Neoplasia, *see* Cancer
Nephrin, 355, 356
Nephritis, *see* Autoimmune nephritis; Glomerulonephritis, NO in; Interstitial nephritis; Lupus nephritis; Mesangial IgA glomerulonephritis, treatment preventing progression of
Nephritogenic autoantibodies in pathogenesis of lupus nephritis, 48-56, 173-177
antigens and, *see* Antigen(s) in lupus nephritis
and cell surface binding to autoantibodies in other autoimmune diseases, 53-54
characteristics of, 48-49, 173-174
and immune deposition, *see* Immune deposits in lupus nephritis
mechanisms of, 175-177
Nephritogenic T cells
in interstitial nephritis, 184-186
see also Effector T cells, nephritogenic
Nephritogenicity in lupus nephritis
of anti-DNA autoantibodies, factors determining, 41-42
see also Nephritogenic autoantibodies in pathogenesis of lupus nephritis; Nephritogenic T cells
Nephrogenic diabetes insipidus (NDI), 314, 344-352
AQP2 and, 542-543
AQP2 gene in, 326, 345, 346, 348-350, 542-543
autosomal dominant, 349
autosomal recessive, 348-349
cellular physiology of AVP antidiuretic action in distal nephron in, 345-346
clinical manifestations of, 344
genetic counseling for, 349
genetics of, 346
treatment of, 349-350
X-linked, 346-348
Nephrolithiasis
supplemental KCl and $KHCO_3$ effects on, 490
see also Nephrolithiasis, risk factor(s) for
Nephrolithiasis, risk factor(s) for, 381-388
cystinuria and primary hyperoxaluria as, 381, 382
familial hyperuricosuria as, 381-383
hypercalciuria as, *see* Hypercalciuria, genetic
Nephron, distal in NDI, cellular physiology of antidiuretic action of AVP in, 345-346
Nephrosis, congenital, genetic testing for, 325
Nephrotic syndrome
AQP2 and, 543-544
diuretics in, 575, 578-580
familial steroid-resistant, 356
Finnish-type congenital, 314, 355-356
Nerves, renal, interaction between angiotensin II, NO and, 246-247
Neuroendocrine disorders in dialyzed ESRD women, 142-143
Neuronal hyperexcitability and degenerescence, K channels in, 446-447
Neuronal nitric oxide synthase, *see* NOS1

Neutral amino acid/glutamate family of K transporters, Na,K-dependent, 451-452
Neutrophil-endothelial cell adhesion in acute renal injury, NO and, 264-265
New millennium, medical care and medicine in, 598-602
Newborns, hazards of diuretics to, 564
NIH (National Institutes of Health), *see* Research in women's health issues
L-NIL, *see* L-N^6-(Iminoethyl)lysine, NOS2 inhibition with
Nitric oxide (NO; endothelium-derived relaxing factor)
  introduction to, 213-214
  sepsis and, 272-276
  see also Acute renal injury, NO in; L-Arginine, role of NO and, in renal function and structure in renal disease; Cell signaling by NO; Glomerulonephritis, NO in; Immunoregulation, NO and; Nitric oxide synthase; Renal hemodynamics, role of NO in; Salt sensitivity, cardiorenal injury, NO and, in hypertension; Tubuloglomerular feedback, NO and
Nitric oxide synthase (NOS)
  blockade of, *see* Renal hemodynamics, role of NO in
  as NO target, 219
  see also Nitric oxide synthase isoforms
Nitric oxide synthase (NOS) isoforms, 230-241
  activity of, in kidney, 232-235
  conclusion on, 238
  expression of, in acute renal injury, 264
  gene products of, *see* Nitric oxide synthase isoforms, gene products of
  regulation of, 235-237
  and synthesis of NO, 217-218
  see also NOS1; NOS2; NOS3
Nitric oxide synthase (NOS) isoforms, gene products of, 230-235
  in kidney, 232-235
  see also NOS1 gene; *NOS2* gene; *NOS3* gene
nNOS (neuronal nitric oxide synthase), *see* NOS1
NO, *see* Nitric oxide
Nongastric H^+,K^+-ATPase (hydrogen, potassium-adenosine triphosphatase), 421-430
  and cation specificity of nongastric pumps, 424-426
  family of, 421-422
  see also Renal H^+,K^+-ATPase
Nongastric pumps
  cation specificity of, 424-426
  see also H,K pumps, renal
Non-Mendelian inheritance of renal disease, 313-315
Nonphysician clinicians (NPCs) in interdisciplinary nephrology health care team, need to include, 102-103
Normal pregnancies, GFR in, 133-135
Normokalemia, K handling along collecting duct in, 390-393
NOS, *see* Nitric oxide synthase
NOS1 (neuronal nitric oxide synthase; nNOS)
  macula densa, regulation of, 257-258
  NO synthesis and, 217-218
  see also NOS1 gene
NOS1 (neuronal nitric oxide synthase; nNOS) gene, 233-236
  expression of, in kidney, 233-234
  knockout of, in acute renal injury, 268
  regulation of, 235-236
  variants of, 231
NOS2 (inducible nitric oxide synthase; iNOS)
  NO synthesis and, 217-218
  in sepsis, 272-276
  see also NOS2, inhibition of, in organ-specific autoimmune disease; NOS2 in acute renal injury; *NOS2* gene; NOS2 in GN
NOS2 (inducible nitric oxide synthase; iNOS), inhibition of, in organ-specific autoimmune disease, 288-293
  in allergic encephalomyelitis, 290-292
  in autoimmune interstitial nephritis, 289-290
NOS2 (inducible nitric oxide synthase; iNOS) in acute renal injury, 265-268
  pathophysiological role of, 265-266
  and therapeutic approaches to limit injury, 267, 268
NOS2 (inducible nitric oxide synthase; iNOS) gene
  expression of, in kidney, 234
  regulation of, 236
  variants of, 231-232
  see also Knockout, NOS2 gene
NOS2 (inducible nitric oxide synthase; iNOS) in GN, 277-285
  mechanisms of induction of, 278-280
NOS3 (endothelial nitric oxide synthase; eNOS), 264
  angiotensin II effects on, 245
  in GN, 277-278, 285
  NO synthesis and, 217-218
  sepsis and, 274, 275
  tubuloglomerular feedback and, 257
  see also NOS3 in acute renal injury; NOS3 gene
NOS3 (endothelial nitric oxide synthase; eNOS) in acute renal injury, 269
  blockade of, as therapeutic approach to limit injury, 267
  in epithelial wound healing, 265
  pathophysiological role of, 266-267
NOS3 (endothelial nitric oxide synthase; eNOS) gene
  expression of, in kidney, 234-235
  knockout of, in acute renal injury, 268
  regulation of, 237
  variants of, 232
NPCs (nonphysician clinicians) in interdisciplinary nephrology health care team, need to include, 102-103
NPHS1 (Finnish-type congenital nephrotic syndrome), 314, 355-356
NPHS1 gene, 355, 356
NPS (nail-patella syndrome), 359
Nuclear localization of anti-DNA antibodies in lupus nephritis through interaction with cell surface antigen, 52-53

O_2^- radicals (oxygen radicals), NO interaction with, 259
Obstruction, ureteral, renal function and structure in, role of L-arginine and NO in, 304-305
OMCD (outer medullary collecting duct), *see* Cation channel(s) in OMCD
Organ-specific autoimmune disease, *see* NOS2, inhibition of, in organ-specific autoimmune disease
Organization of collecting duct system, 390-391
Osteopontin in lupus nephritis, 61
Osteoporosis
  corticosteroid-induced, in lupus nephritis, renal transplantation and, 81-82
  supplemental KCl and $KHCO_3$ effects on, 490-491
  see also Osteoporosis in ESRD women

Osteoporosis in ESRD women, 115-122
bone measurement in, 119-120
on dialysis, 144
pathophysiology of, 115-116
risk factors for, 116-119
therapy of, 120
Ototoxicity, drug-induced, 564
Outcome
lupus nephritis, race and, 3-4
see also Mortality; Prognosis; Survival *and specific conditions*
Outer medullary collecting duct, *see* Cation channel(s) in OMCD
Oxygen radicals (O_2^- radicals), NO interaction with, 259

Pain with ADPKD, causes and management of, 124
Parenchymal cells, T cell interactions with, cellular immunity in lupus nephritis and, 179-180
Passive apoptosis, and autoimmunity induction, 28
Path clamp study of cation channels in OMCD, 472-473
Pathophysiology and pathogenesis
of autoimmunity, *see* Lymphocyte tolerance to self-antigens, pathogenesis of autoimmunity and
disease mechanisms and, of lupus nephritis, 20-22; *see also* Apoptosis, and autoimmunity in lupus nephritis; Cellular immunity in lupus nephritis; Humoral immunity in lupus nephritis; Lymphocyte tolerance to self-antigens in lupus nephritis; Nephritogenicity in lupus nephritis; Renal cytokines and chemokines in pathogenesis of lupus nephritis
of osteoporosis in ESRD women, 115-116
see also AQP2 in pathophysiological states; Pathophysiological role of NOS in acute renal injury; Progression of ADPKD in women, pathophysiological factor(s) associated with
Pathophysiological role of NOS in acute renal injury, 265-267
of NOS2, 265-266
of NOS3, 266-267
Patient survival with ESRD
of ESRD women on dialysis, 140-142
short-term, in renal transplantation for lupus nephritis-induced ESRD, 77-78
Perinatal milieu, acquired hypertension and cardiorenal disease and, 205-208
Peripheral lymphocyte tolerance to self-antigens
mechanisms of, 26-28
see also Peripheral lymphocyte tolerance to self-antigens, breakdown of
Peripheral lymphocyte tolerance to self-antigens, breakdown of, 28-30
of anergy mechanisms, 28-29
of deletional mechanisms, 28
of immunoregulation, 30
lupus as breakdown of, 35-36, 42; *see also* Lupus nephritis
and polyclonal lymphocyte activation, 30
Permeability of K^+ in CCD principal cells, developmental regulation of K^+ transport and, 160-162
Persistent fetal *PKD-1* gene expression, and progression of ADPKD, 129
Phenotypes
of cytokines and cytokine receptor in knockout mice, endogenous NO production and, 293
inflammatory, in lupus nephritis, antigenic specificity influencing, 50-51
Phenytoin reducing hematuria in IgA glomerulonephritis, 168
PHEX gene in hypophosphatemic rickets, 365-367
Physical activity, decrease of, as risk factor for osteoporosis in ESRD, 116-117
Physiology
cellular, of AVP antidiuretic action in distal nephron in NDI, 345-346
of colonic H,K-ATPase, 406-408
PKD, *see* Polycystic kidney disease
PKD1 gene in ADPKD
discovery of, 328
genetic analysis of, 328-332
interaction between PKD1 protein and, mutations and, 129-131
and mechanisms of cyst formation, 337, 338
and progression of ADPKD, 129-131
PKD1 protein, 332-336
analyzed, 332-334
interaction between *PKD1* gene and, mutations and, 129-131
and mechanisms of cyst formation, 337, 338
and pathways to PKD, 335-336
PKD2 gene in ADPKD
discovery and genetic analysis of, 334
interaction between PKD2 protein and, mutations and, 129-131
and progression of ADPKD, 129-131
PKD2 protein
analyzed, 334-335
interaction between *PKD2* gene and, mutations and, 129-131
and pathways to PKD, 335-336
Planning for research in women's health issues, 107-108
Plasticity of H^+-ATPase polarity, kAE1 and, and hensin pathway in intercalated cells, 415-416
Platelet function, dietary K effects on, 480
Polarity
defective epithelial, and ADPKD progression, 128
see also Polarity of intercalated cells, hensin pathway and
Polarity of intercalated cells, hensin pathway and
cell-type-specific targeting and, 416
kAE1 and plasticity of H^+-ATPase, 415-416
reversal of, 419
Polyclonal lymphocyte activation, autoimmunity and, 30
Polycystic kidney disease (PKD)
genetic testing for, 324
see also Autosomal dominant polycystic kidney disease
Polycystic liver disease, *see* Cystic liver disease with ADPKD
Polygenic inheritance of renal disease, 313
Polymorphism(s)
ENaC disorders due to, 374-376
genetic testing complicated by, 321-322
see also specific genes and conditions
Pore(s), ENAC, interaction between amiloride and, 527-528
Pore-forming K (potassium) channels, cloned, 441-442
Positional candidate approach in disease-gene identification, 316
Positional cloning, disease-gene identification with, 316
Post-diuretic NaCl (sodium chloride) retention, and diuretic resistance, 583-585
Potassium, *see* K

Potassium chloride, *see* Supplemental KCl and $KHCO_3$, effects of
Pragmatic interventions to improve environment for women in nephrology, 96
Pregnancy
and ADPKD, 126
in dialyzed ESRD women, 144
hazards of diuretics in, 564
perinatal milieu and acquired hypertension and cardiorenal disease, 205-208
see also Gestational glomerular filtration rate; Pregnancy, renal complications of
Pregnancy, renal complications of
need for research on, 107
see also Maternal renal function, long-term renal effects of pregnancy and
Premolecular era, genetic studies of blood pressure control in, 201-202
Prenatal (antenatal) diagnosis, ethical issues in, 322-323
Prenatal (antenatal) hypercalciuric Bartter's syndrome (hyperprostaglandin E syndrome), 367-369
Presymptomatic diagnosis, ethical issues in, 322-323
Preventive interventions
to improve environment for women in nephrology, 96
see also Mesangial IgA glomerulonephritis, treatment preventing progression of
Primary hyperoxaluria, as risk factor for nephrolithiasis, 381, 382
Priming of T cells in lupus nephritis, 182-184
Principal cells of CCDs, developmental regulation of K^+ transport in, 158-162
Priority setting for research in women's health issues, 105
Privacy issue in genetic testing, 323
Professional opportunities, enhancing women's, as WIN goal, 211
Prognosis
lupus nephritis, 4-5
see also Outcome
Programmed cell death, *see* Apoptosis
Progression of ADPKD in women, pathophysiological factor(s) associated with, 126-132
cell proliferation as, 126-127
ECM abnormalities as, 129
epithelial polarity defects as, 128
ion and fluid secretion as, 127-128
mutations of *PKD-1* and *PKD-2* genes and their interactions with proteins as, 129-131
persistent fetal *PKD-1* gene expression as, 129
Progression of renal disease, *see* Mesangial IgA glomerulonephritis, treatment preventing progression of; Progression of ADPKD in women, pathophysiological factor(s) associated with
Progressive renal damage, role of RAS in, 150-153
Proliferation
neointima, dietary K protection against, 483
of VSMCs, dietary K protection against, 479-480
see also Proliferative lupus nephritis
Proliferative lupus nephritis
natural history of, 2-3
therapy of, 6-7
Protective effects of dietary K, *see* Vascular protective effects of dietary K
Protein(s)
associated with ancillary subunits of K channels, 442-444
specifically cleaved, or with role in apoptosis, autoantigens including, 40-41
see also Cotransporter genes and proteins in NaCl transport; Major intrinsic protein/AQP family; PKD1 protein; PKD2 protein; Proteinuria
Proteinuria in mesangial IgA glomerulonephritis, preventing disease progression with treatment to reduce, 169-170
Proton ATPase (adenosine triphosphatase)
renal acid excretion by, in dRTA, 189
see also H^+-ATPase; H^+,K^+-ATPase
Pseudohypoaldosteronism type 1a (autosomal dominant), 314, 376-377
Pseudohypoaldosteronism type 1b (autosomal recessive), 314, 376

Race, and lupus nephritis outcome, 3-4
RANTES (regulated upon activation, normal T cell expressed and secreted) in lupus nephritis, 60-61
RAS, *see* Renin-angiotensin system
Reabsorption, K^+, in collecting ducts, molecular mechanisms responsible for, 394-395
Reactivity of NO and, cell signaling and, 218-219
Receptors
as NO targets, 220
see also specific receptors
Recurrence, lupus nephritis, in renal graft, 78-79
Recycling, K, across tubular apical and basolateral membranes, K channels and, 460-461
Relapse, lupus nephritis, 5-6
Remission, lupus nephritis, 5
Remnant kidney, renal function and structure in, role of L-arginine and NO in, 305-306
Renal cell carcinoma
genetic testing for, 325
inheritance of, 315
Renal cytokines and chemokines in pathogenesis of lupus nephritis, 57-66, 180
in cell activation, 62-63
in cell adhesion, 61-62
cellular immunity and, 180
hematopoietic growth factors and, *see* Hematopoietic growth factors in lupus nephritis
in recruitment of inflammatory leukocytes, 60-61
role of, in fibrosis, 63
sources of, 57
Renal damage, progressive, role of RAS in, 150-153
Renal development
fetal, RAS in, 148-150
see also Maturing kidney, regulation of K^+ transport in
Renal disease
MIP/AQP family and, 541-542
see also L-Arginine, role of NO and, in renal function and structure in renal disease; Genetic diseases, renal *and specific conditions*
Renal effects of pregnancies, *see* Maternal renal function, long-term renal effects of pregnancy and

Renal epithelium, *see* Terminal differentiation in epithelia, hensin and *and entries beginning with term*: Epithelial
Renal failure
in women, need for research on, 106-107
see also End-stage renal disease in women; Renal transplantation for lupus nephritis-induced ESRD
Renal function
effects of chronic NOS blockade on, 247-248
see also L-Arginine, role of NO and, in renal function and structure in renal disease; Maternal renal function, long-term renal effects of pregnancy and *and specific aspects of renal function*
Renal hemodynamics, *see* Glomerular filtration rate; Renal hemodynamics, role of NO in
Renal hemodynamics, role of NO in, 242-250
angiotensin II and, *see* Angiotensin II-NO interaction
and effects of chronic NOS blockade on renal function, 247-248
in Na excretion, 247
in RPF and GFR regulation, 242-244
Renal H^+,K^+-ATPase (hydrogen, potassium-adenosine triphosphatase), 399-404
in dRTA, 189-193
K^+-ATPase activities and, 402-403
molecular identification of, 431-437
and regulation of $HK\alpha_2$ in renal medulla by chronic hypokalemia, 400-402
α-subunit of, *see* Alpha (α)-subunit of renal H^+,K^+-ATPase
β-subunit of, cDNA clones of, 434-436
Renal H,K pumps, *see* H,K pumps, renal
Renal injury, *see* Acute renal injury, NO in; Salt sensitivity, cardiorenal injury, NO and, in hypertension *and specific conditions*
Renal ischemia in acute renal injury, effects of *NOS2* gene knockout on, 268-269
Renal K (potassium), role of renal K channels in secretion of, 461; *see also* Renal K channels
Renal K (potassium) channels, 458-471
in CCDs, 463-465
distribution and regulation of, 461-462
future challenges concerning, 468-469
molecular structure of, 465-468
and renal K secretion, 461
role of, in tubular cells, *see* Tubular cells, role of K channels in
in TAL of Henle's loop, 462-463
Renal medulla, *see* Cation channel(s) in OMCD; Medulla
Renal membranes, *see* Citrate transport across renal and intestinal membranes
Renal morphological alterations due to K^+ depletion, 395
Renal nerves, interaction between angiotensin II, NO and, 246-247
Renal patient population, need for nephrologists to reflect, 100-101
Renal plasma flow (RPF)
NO in regulation of, 242-244
in normal pregnancy, 133-135
Renal structure
K^+ depletion-induced changes in, 395-396
see also L-Arginine, role of NO and, in renal function and structure in renal disease
Renal transplantation for lupus nephritis-induced ESRD, 77-85
aPL antibodies and, 79
with living-related donor kidneys, 78
and lupus recurrence in graft, 78-79
risk factors for long-term morbidity and mortality with, 79-82
short-term patient and graft survival with, 77-78
timing of, and disease activity, 78
Renal tubules, *see* Tubules
Renal tumors
genetic testing for, 325
see also Renal cell carcinoma; Wilms' tumor
Renin
angiotensin II-NO interaction effects on secretion of, 246
role of renin gene in hypertension, 202-203
see also Renin-angiotensin-aldosterone system; Renin-angiotensin system
Renin-angiotensin-aldosterone system, and chronic adaptation to diuretics, 586
Renin-angiotensin system (RAS), 148-154
in fetal renal development, 148-150
in progressive renal damage, 150-153
Renin-angiotensin system (RAS) genes, hypertension and, 201-204
Research in women's health issues, 105-108
advocacy for, as WIN goal, 211
on causes of renal failure, 106-107
on ESRD, 106
planning processes for, 107-108
setting priorities for, 105
on social issues and equity of access to care, 107
Reversal of polarity of intercalated cells, 419
Rickets, hypophosphatemic, 314, 365-367
Risk(s)
of diuretics to newborns and in pregnancy, 564
see also Risk factors
Risk factors
for long-term morbidity and mortality with renal transplantation for lupus nephritis-induced ESRD, 79-82
for nephrolithiasis, *see* Nephrolithiasis, risk factor(s) for
for osteoporosis in ESRD women, 116-119
RPF, *see* Renal plasma flow

Salt (NaCl) sensitivity, cardiorenal injury, NO and, in hypertension, 296-303
animal and human studies of, 299-302
role of intrarenal NO, 296-297
vascular remodeling and, 298-299
Sclerosis, diffuse mesangial, DDS and, 357
Self-antigens, *see* Lymphocyte tolerance to self-antigens, pathogenesis of autoimmunity and
Sepsis, NO and, 272-276
Sequestering antigens, uncovering of, and autoimmunity, 29-30
Sexual dysfunction
in dialyzed ESRD women, 143
diuretic-induced impotence, 564
Short-term adaptation to diuretics, 583-585
Short-term survival of graft and patient with renal transplantation for lupus nephritis-induced ESRD, 77-78
Signal amplification systems, as NO targets, 220
Single cation channel in OMCD, 473-475

Single-gene abnormalities in Mendelian forms of hypertension, 204-205
Site of action of NO in tubuloglomerular feedback, 255-257
SLC3A1 gene in cystinuria, 365
SLE (systemic lupus erythematosus), *see* Lupus nephritis
Smooth muscle cells, vascular, dietary K protection against proliferation of, 479-480
Social issues affecting women, need for research on, 107
Sodium, *see* Na
Sodium chloride, *see* Diuretics; Salt sensitivity, cardiorenal injury, NO and, in hypertension
Steroid(s)
  familial steroid-resistant nephrotic syndrome, 356
  mesangial IgA glomerulonephritis progression prevented with, 168, 169, 171
  see also Apparent mineralocorticoid excess syndrome; Corticosteroids; Glucocorticoid-remediable aldosteronism
Steroid-resistant nephrotic syndrome, familial, 356
Stones, kidney, *see* Nephrolithiasis
Strategic interventions to improve environment for women in nephrology, 96-97
Stress-inducible factors, effects of acute renal injury on, 263
Stroke, supplemental KCl and $KHCO_3$ effects on, 491-492
Structural changes, renal, induced by K^+ depletion, 395-396
Supplemental K (potassium)
  effects of, on hypertension, 494-499
  see also Supplemental KCl and $KHCO_3$, effects of
Supplemental KCl (potassium chloride) and $KHCO_3$ (potassium carbonate), effects of, 487-493
  on hypertension, 488-489
  on kidney stones, 490
  on osteoporosis, 490-491
Suppression mechanism, peripheral lymphocyte tolerance to self-antigens and, 27-28
Surface cells, colonic H^+,K^+-ATPase distribution in, 407-408
Survival
  short-term graft, in renal transplantation for lupus nephritis-induced ESRD, 77-78
  see also Patient survival with ESRD
Systemic autoimmunity in lupus nephritis, genetic basis of, 14-17
Systemic lupus erythematosus, *see* Lupus nephritis

T cells
  endogenous NO as antiproliferative agent for, 292-294
  in lupus nephritis, interactions of, with macrophages and parenchymal cells, 178-180; *see also entries beginning with terms*: Lymphocyte tolerance
  see also Costimulatory molecules; Interstitial nephritis, T cells in; Nephritogenic T cells
Table salt, *see* Diuretics; Salt sensitivity, cardiorenal injury, NO and, in hypertension
TAL, *see* Thick ascending limb of Henle's loop
Targeting, cell-type specific, hensin pathway in intercalated cells and, 416
Technology transfer in genetic testing, 323-324
Terminal differentiation in epithelia, hensin and
  hensin involvement in, 418-419
  reversal of polarity and, 419
  see also Hensin pathway in intercalated cells
TGF-β1 (transforming growth factor-β1), failure of immunoregulation mediated by, autoimmunity and, 30
Therapy
  of Bartter's syndromes, 369
  of clinical manifestations of ADPKD, 124-126
  of cystinuria, 365
  of dRTA, 371
  of extracellular CaR inherited disorders, 370
  of Fabry disease, 359
  of Gitelman syndrome, 370
  to limit acute renal injury and improve renal hemodynamics, 267
  of NDI, 349-350
  of NPS, 359
  nutritional, *see* Supplemental K
  of osteoporosis in ESRD women, 120
  see also Dialysis for ESRD women; Immunosuppressive therapy of lupus nephritis; Mesangial IgA glomerulonephritis, treatment preventing progression of; Renal transplantation for lupus nephritis-induced ESRD; Therapy of diuretic resistance
Therapy of diuretic resistance, 589-595
  with combination diuretics, 590-593
  with continuous diuretic infusions, 593-595
  with high dose diuretics, 589-590
  with ultrafiltration, 595
Thiazide diuretics
  clinical uses of, 555
  effects of, on Ca metabolism, 553-555
  inhibiting DCT NaCl transport, 513-516
Thick ascending limb (TAL) of Henle's loop
  developmental regulation of K^+ transport in, 157
  K channels in, 462-463
  see also Loop diuretics, TAL NaCl transport inhibited by
Thin membrane nephropathy (thin glomerular basement membrane disease), 354
Thrombosis, coronary artery, dietary K protection against, 480-482
Thromboxane receptors, NO interaction with, 259
Timing of renal transplantation for lupus nephritis-induced ESRD, 78
TNF-α (tumor necrosis factor-α), and cell adhesion in lupus nephritis, 61-62
Tolerance to self-antigens, *see* Lymphocyte tolerance to self-antigens, pathogenesis of autoimmunity and
Tonsillectomy reducing hematuria in IgA glomerulonephritis, 168
Trainees, nephrology, attracting, 99-100
Transcription factors, as NO targets, 221
Transepithelial voltage, and Na^+ absorption in principal cells of CCDs, developmental regulation of K^+ transport and, 158-159
Transforming growth factor-β1 (TGF-β1), failure of immunoregulation mediated by, autoimmunity and, 30
Transplantation, *see* Renal transplantation for lupus nephritis-induced ESRD
Transport
  general transport properties of collecting duct subsegments, 391
  see also Citrate transport across renal and intestinal membranes; Cotransporters; Molecular mechanisms of diuretics

inhibiting NaCl transport; Transport, K; Tubular transport disorder(s), inherited
Transport, K, 391-393
along collecting duct, molecular mechanisms of, 392-393
and general transport properties of collecting duct subsegment, 391
see also K transporters; Maturing kidney, regulation of K^+ transport in
Treatment, *see* Therapy
TSC (tuberous sclerosis complex), genetic testing for, 325
TSC1 gene in TSC, 325
TSC2 gene in TSC, 325
Tuberous sclerosis complex (TSC), genetic testing for, 325
Tubular acidosis, *see* Distal renal tubular acidosis
Tubular cells, *see* Apical membranes of tubular cells; Basolateral membranes of tubular cells; Tubular cells, role of K channels in
Tubular cells, role of K channels in, 458-460
in maintenance of negative electrical potential of cells, 458-459
in regulation of cell volume, 459-460
Tubular transport disorder(s), inherited, 364-373
Bartter's-like syndromes as, 314, 367-370, 385
cystinuria as, 314, 364-365
dRTA as, 370-371; *see also* Distal renal tubular acidosis
of extracellular CaR, 370
hypophosphatemic rickets as, 314, 365-367
Tubules
connecting, *see* Cortical collecting ducts, regulation of K^+ transport in maturing
distal convoluted, thiazide diuretics inhibiting NaCl transport in, 513-516
see also entries beginning with element: Tubul-
Tubuloglomerular feedback, NO and, 251-262
evidence for NO role in, 253-254
and macula densa nNOS regulation, 257-258
NO interactions with vasoactive agents and, 258-259
NO as mediator or modulator in, 254-255
site of action of NO, 255-257
Tubulointerstitium, *see* Interstitial nephritis, T cells in
Tumor necrosis factor-α (TNF-α), and cell adhesion in lupus nephritis, 61-62
Two-hit model of ADPKD, clinical implications of, 340-341
Type 1a (autosomal dominant) pseudohypoaldosteronism, 314, 376-377
Type 1b (autosomal recessive) pseudohypoaldosteronism, 314, 376

Ubiquitous cell surface antigens, nuclear localization of anti-DNA antibodies in lupus nephritis through interaction with, 52-53
Ultrafiltration for diuretic resistance, 595
Uniparental disomy, and renal disease, 315
Ureteral obstruction, renal function and structure in, role of L-arginine and NO in, 304-305

V2R gene in NDI, 346, 347, 349, 350
Vascular disease, accelerated, as risk factor for morbidity and mortality with renal transplantation for lupus nephritis, 79-81
Vascular protective effects of dietary K, 477-486
against arteriosclerotic lesions, 478, 482, 484
and cellular actions of K, 478-480
against coronary artery thrombosis, 480-482
in humans, 477
and K regulation, 477-478
against neointimal lesion formation and neointima proliferation, 478, 482-485
Vascular remodeling in hypertension, NO and, 298, 299
Vascular smooth muscle cells (VSMCs), dietary K protection against proliferation of, 479-480
Vasoactive agents
NO interaction with, 258-259
see also Angiotensin II-NO interaction
Vasopressin, antidiuretic action of, in distal nephron in NDI, cellular physiology of, 345-346
VDR (vitamin D receptor) gene in hypercalciuria, 385, 386
Vitamin D-resistant (hypophosphatemic) rickets, 314, 365-367
Volume, tubular cell, role of K channels in regulation of, 459-460
Von Hippel Lindau syndrome, genetic testing for, 325
VSMCs (vascular smooth muscle cells), dietary K protection against proliferation of, 479-480

Warfarin, IgA glomerulonephritis progression prevented with, 169, 171
Water flux, *see* Aquaporin mediated water flux
Wilms' tumor (WT), 357
genetic testing for, 325
inheritance of, 325
WIN (Women in Nephrology), goals of, 211-212
Women in nephrology
in administrative leadership positions, 109-114
history of (1918-1960), 89-94
introduction to, 87-88
and WIN goals, 211-212
see also Autosomal dominant polycystic kidney disease in women; Citrate transport across renal and intestinal membranes; Distal renal tubular acidosis; End-stage renal disease in women; Environment for women in nephrology, improving; Genetic hypertension and cardiorenal disease; Gestational glomerular filtration rate; Interstitial nephritis, T cells in; Lupus nephritis; Maturing kidney, regulation of K^+ transport in; Mesangial IgA glomerulonephritis, treatment preventing progression of; Need(s) in nephrology; Renin-angiotensin system genes; Research in women's health issues
Women in Nephrology (WIN), goals of, 211-212
Wound healing, epithelial, NO in, 265
WT, *see* Wilms' tumor
WT1 gene
in DDS, 356, 357
in Frasier syndrome, 358
in Wilms' tumor, 325

X-linked nephrogenic diabetes insipidus (NDI), 346-348
X-linked nephrolithiasis (Dent's disease), 314, 384-385